HD MEDICINE’s Strategic Position in the 12th National Drug Centralized Procurement Round

HD MEDICINE (stock code 000963.SZ) has announced its participation in the 12th round of the national drug centralized procurement (国采), a key policy initiative aimed at curbing pharmaceutical costs while ensuring the availability of essential medicines across China’s public hospitals. The company’s announcement, released on 3 August 2026, confirms that it has achieved provisional selection for several high‑demand drug categories. This development signals a decisive step forward for HD MEDICINE’s commercial pipeline and positions the firm favorably amid a rapidly evolving health‑care landscape.

1. The National Drug Centralized Procurement Framework

The Ministry of Human Resources and Social Security and the National Health Commission have been rolling out successive procurement rounds since 2018. The 12th round, which opened bidding on 31 July 2026 and concluded with provisional selections on 2 August, covered 65 clinical‑use drugs spanning anti‑infectious, anti‑cancer, anti‑thrombotic, anti‑diabetic, anti‑hypertensive, lipid‑lowering, and rheumatologic agents. The procurement process is highly competitive, with an average of 15 bidders per drug and a clear emphasis on price rationality and quality assurance.

Key policy highlights for this round include:

  • Brand‑specific allocation – Hospitals can specify preferred manufacturers, ensuring that established brands secure market share.
  • “Non‑quantity revival” rule – Reference drugs that fail to win full bids can still be selected without volume commitment, preserving access to critical therapies.
  • Enhanced quality oversight – Each drug must pass rigorous domestic and international quality checks before inclusion in the procurement list.

These reforms aim to reduce price volatility, tighten supply chains, and protect patients’ drug access, thereby creating a more predictable revenue environment for participating manufacturers.

2. HD MEDICINE’s Provisional Selections

While the announcement does not detail the exact drug names, it confirms that HD MEDICINE has secured provisional selection in multiple therapeutic areas. The company’s product portfolio—encompassing antibiotics, proprietary Chinese medicines, chemical synthetic drugs, and genetically engineered agents—aligns closely with the procurement list’s focus on common and high‑volume drugs.

Implications of provisional selection:

  • Revenue acceleration – Contracts in the national procurement program typically involve substantial purchase volumes, which can significantly boost sales and cash flow within the next fiscal cycle.
  • Market penetration – Inclusion in the procurement list offers a direct channel into public hospitals nationwide, accelerating the company’s distribution reach.
  • Competitive advantage – By successfully navigating the rigorous bid process, HD MEDICINE demonstrates manufacturing capacity, quality compliance, and pricing competitiveness—all critical factors for long‑term sustainability.

3. Strategic Fit with HD MEDICINE’s Growth Trajectory

3.1. Portfolio Synergy

HD MEDICINE’s focus on both traditional Chinese medicine and modern biopharmaceuticals positions it well to capture the diversified demand reflected in the procurement list. The company’s recent expansion into genetically engineered drugs signals a shift toward value‑added therapeutics, aligning with the Ministry’s intent to foster innovation within the procurement framework.

3.2. Scale and Cost Discipline

With a market capitalization of 50.1 billion CNY and a price‑earnings ratio of 14.31, the company sits comfortably within the mid‑cap segment of the healthcare providers sector. Its production footprint in Hangzhou enables efficient scale‑up of new drug manufacturing, while its focus on cost‑effective production methods helps maintain competitive pricing—an essential factor in the tightly regulated procurement arena.

3.3. Financial Position

The close price of 28.57 CNY on 2 August, coupled with a 52‑week low of 25.63 CNY, indicates a valuation that remains attractive for investors seeking exposure to a company poised for upside driven by policy‑backed contracts. The company’s stable earnings trajectory and modest price‑earnings ratio suggest that market sentiment is likely to remain supportive as the procurement contracts materialize.

4. Forward‑Looking Outlook

4.1. Immediate Revenue Impact

Assuming the conversion of provisional selections into signed contracts within the next quarter, HD MEDICINE can expect a measurable uptick in its sales pipeline. The national procurement program’s volume commitments often translate into multi‑million‑CNY contracts, providing a cushion against market volatility.

4.2. Long‑Term Growth Trajectory

Beyond the immediate revenue boost, HD MEDICINE’s entry into the national procurement channel strengthens its bargaining position for future rounds. The company can leverage its expanded distribution network and proven compliance record to secure additional drug selections in subsequent procurement cycles.

4.3. Risks and Mitigation

  • Regulatory compliance – The company must continuously meet evolving quality and reporting standards; any lapses could jeopardize contract fulfillment.
  • Competitive pressure – While HD MEDICINE has secured provisional selections, rivals may still win full bids for overlapping products, potentially diluting market share.
  • Cost control – Sustained profitability hinges on maintaining lean manufacturing processes; escalation in raw material costs could erode margins.

To mitigate these risks, HD MEDICINE should reinforce its quality assurance systems, diversify its product pipeline to include both high‑volume generics and specialty therapeutics, and monitor supplier contracts closely to safeguard cost stability.

5. Conclusion

HD MEDICINE’s provisional selection in the 12th national drug centralized procurement round marks a pivotal milestone in the company’s evolution from a regional manufacturer to a nationally recognized pharmaceutical supplier. The announcement reflects strategic alignment with government initiatives aimed at rationalizing drug prices while ensuring access to essential medicines. Coupled with the company’s robust financial foundation and diversified product mix, this development is poised to generate significant upside for stakeholders and cement HD MEDICINE’s position as a key player in China’s healthcare sector.